"The favorable tolerability and pharmacokinetic profile observed with CVN293 in this first-in-human study are promising ...

Cerevance’s attempt to unlock the first-line Parkinson's disease market has hit a snag, with solengepras performing no better ...

The ASCEND trial evaluated the safety, tolerability, and efficacy of solengepras and aimed to establish its potential to ...

The pivotal, Phase III study will evaluate the change in average daily “OFF” time in Parkinson's patients dosed with ...

Solengepras shows strong potential as an adjunctive therapy for Parkinson’s, offering a novel, well-tolerated option with ...

Additional Cerevance Presentations at AAN 2025 The company presented a poster demonstrating the potential of its proprietary NETSseq platform to identify and/or validate cell-specific gene targets ...

CVN293 was generally well-tolerated in healthy volunteers with evidence of robust brain penetration, supporting utility of KCNK13 inhibitors for neurodegenerative diseases characterized by neuroinflam ...

Cerebrospinal fluid (CSF) sampling demonstrated high levels of central nervous system (CNS) exposure with CVN293. Additional Cerevance Presentations at AAN 2025 The company presented a poster ...